6 |
INDUSTRY INSIGHTS................................................................................................................ 47 |
|||
• 6.1 |
INTRODUCTION............................................................................................................................................................... 48 |
|||
• 6.2 |
INDUSTRY TRENDS......................................................................................................................................................... 48 |
|||
• 6.2.1 |
GROWING MARKET DEMAND FOR HUMAN INSULIN PENS......................................................................... 48 |
|||
• 6.2.2 |
INCREASING MARKET FOCUS ON THE PIPELINE DEVELOPMENT OF |
|||
NOVEL HUMAN INSULIN THERAPIES........................................................................................................... 49 | ||||
• 6.3 |
PIPELINE ANALYSIS......................................................................................................................................................... 51 |
|||
• 6.3.1 |
BY COMPANY................................................................................................................................................ 51 |
|||
• 6.3.2 |
BY CLINICAL TRIAL PHASE........................................................................................................................... 52 |
|||
• 6.3.3 |
PORTER’ S FIVE FORCE ANALYSIS................................................................................................................. 53 |
|||
• 6.3.3.1 |
THREAT FROM NEW ENTRANTS.............................................................................................. 54 |
|||
• 6.3.3.2 |
THREAT FROM SUBSTITUTES.................................................................................................. 54 |
|||
• 6.3.3.3 |
BARGAINING POWER OF BUYERS........................................................................................... 54 |
|||
• 6.3.3.4 |
BARGAINING POWER OF SUPPLIERS...................................................................................... 55 |
|||
• 6.3.3.5 |
INTENSITY OF COMPETITIVE RIVALRY.................................................................................... 55 |
|||
7 |
GLOBAL HUMAN INSULIN MARKET, BY PRODUCT TYPE......................................................... 56 |
|
• 7.1 |
INTRODUCTION............................................................................................................................................................... 57 |
|
• 7.2 |
HUMAN INSULIN DRUGS................................................................................................................................................ 58 |
|
• 7.3 |
HUMAN INSULIN DELIVERY DEVICES............................................................................................................................. 59 |
|
8 |
GLOBAL HUMAN INSULIN DRUGS MARKET, BY TYPE............................................................. 61 |
||
• 8.1 |
INTRODUCTION............................................................................................................................................................... 62 |
||
• 8.2 |
INSULIN ANALOGS AND BIOSIMILARS........................................................................................................................... 62 |
||
• 8.2.1 |
LONG-ACTING............................................................................................................................................... 64 |
||
• 8.2.2 |
RAPID-ACTING.............................................................................................................................................. 66 |
||
• 8.2.3 |
PREMIXED..................................................................................................................................................... 67 |
||
• 8.3 |
HUMAN INSULIN BIOLOGICS.......................................................................................................................................... 68 |
||
• 8.3.1 |
SHORT-ACTING............................................................................................................................................. 70 |
||
• 8.3.2 |
INTERMEDIATE-ACTING................................................................................................................................ 71 |
||
• 8.3.3 |
PREMIXED..................................................................................................................................................... 72 |
||
• | |||